Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Infectious Diseases
Published in: BMC Infectious Diseases 1/2010

Open Access 01-12-2010 | Research article

Predictors of persistently positive Mycobacterium-tuberculosis-specific interferon-gamma responses in the serial testing of health care workers

Published in: BMC Infectious Diseases | Issue 1/2010

Login to get access

Abstract

Background

Data on the performance of Mycobacterium-tuberculosis-specific interferon-(IFN)-γ release assays (IGRAs) in the serial testing of health care workers (HCWs) is limited. The objective of the present study was to determine the frequency of IGRA conversions and reversions and to identify predictors of persistent IGRA positivity among serially tested German HCWs in the absence of recent extensive tuberculosis (TB) exposure.

Methods

In this observational cohort-study HCWs were prospectively recruited within occupational safety and health measures and underwent a tuberculin skin test (TST) and the IGRA QuantiFERON®-TB Gold In-Tube (QFT-GIT) at baseline. The QFT-GIT was repeated 18 weeks later in the median. QFT-GIT conversions (and reversions) were defined as baseline IFN-γ < 0.35 IU/ml and follow-up IFN-γ ≥ 0.35 IU/ml (and vice versa). Predictors of persistently positive QFT-GIT results were calculated by logistic regression analysis.

Results

In total, 18 (9.9%) and 15 (8.2%) of 182 analyzed HCWs were QFT-GIT-positive at baseline and at follow-up, respectively. We observed a strong overall agreement between baseline and follow-up QFT-GIT results (κ = 0.70). Reversions (6/18, 33.3%) occurred more frequently than conversions (3/162, 1.9%). Age and positive prior and recent TST results independently predicted persistent QFT-GIT positivity. Furthermore, the chance of having persistently positive QFT-GIT results raised about 3% with each additional 0.1 IU/ml increase in the baseline IFN-γ response (adjusted odds ratio 1.03, 95% confidence interval 1.01-1.04). No active TB cases were detected within an observational period of more than two years.

Conclusions

The QFT-GIT's utility for the application in serial testing was limited by a substantial proportion of reversions. This shortcoming could be overcome by the implementation of a borderline zone for the interpretation of QFT-GIT results. However, further studies are needed to clearly define the within-subject variability of the QFT-GIT and to confirm that increasing age, concordantly positive TST results, and the extend of baseline IFN-γ responses may predict the persistence of QFT-GIT positivity over time in serially tested HCWs with only a low or medium TB screening risk in a TB low-incidence setting.
Appendix
Available only for authorised users
Literature
1.
American Thoracic Society: Targeted tuberculin testing and treatment of latent tuberculosis infection. MMWR Recomm Rep. 2000, 49: 1-51.
2.
Mack U, Migliori GB, Sester M, Rieder HL, Ehlers S, Goletti D, Bossink A, Magdorf K, Holscher C, Kampmann B, et al: LTBI: latent tuberculosis infection or lasting immune responses to M. tuberculosis? A TBNET consensus statement. Eur Respir J. 2009, 33: 956-973. 10.1183/09031936.00120908.CrossRefPubMed
3.
Diel R, Seidler A, Nienhaus A, Rusch-Gerdes S, Niemann S: Occupational risk of tuberculosis transmission in a low incidence area. Respir Res. 2005, 6: 35-10.1186/1465-9921-6-35.CrossRefPubMedPubMedCentral
4.
Menzies D, Joshi R, Pai M: Risk of tuberculosis infection and disease associated with work in health care settings. Int J Tuberc Lung Dis. 2007, 11: 593-605.PubMed
5.
Menzies D: Interpretation of repeated tuberculin tests. Boosting, conversion, and reversion. Am J Respir Crit Care Med. 1999, 159: 15-21.CrossRefPubMed
6.
Menzies D, Pai M, Comstock G: Meta-analysis: new tests for the diagnosis of latent tuberculosis infection: areas of uncertainty and recommendations for research. Ann Intern Med. 2007, 146: 340-354.CrossRefPubMed
7.
Pai M, Joshi R, Dogra S, Mendiratta DK, Narang P, Kalantri S, Reingold AL, Colford JM, Riley LW, Menzies D: Serial testing of health care workers for tuberculosis using interferon-gamma assay. Am J Respir Crit Care Med. 2006, 174: 349-355. 10.1164/rccm.200604-472OC.CrossRefPubMedPubMedCentral
8.
Diel R, Forssbohm M, Loytved G, Haas W, Hauer B, Maffei D, Magdorf K, Nienhaus A, Rieder HL, Schaberg T, et al: [Recommendations for environmental contact tracing in tuberculosis. German Central Committee against Tuberculosis]. Gesundheitswesen. 2007, 69: 488-503. 10.1055/s-2007-980089.CrossRefPubMed
9.
Centers for Disease Control and Prevention: Guidelines for the investigation of contacts of persons with infectious tuberculosis; recommendations from the National Tuberculosis Controllers Association and CDC, and Guidelines for using the QuantiFERON®-TB Gold test for detecting Mycobacterium tuberculosis infection, United States. MMWR Recomm Rep. 2005, 54 (RR-15): 1-55.
10.
Hill PC, Brookes RH, Fox A, Jackson-Sillah D, Jeffries DJ, Lugos MD, Donkor SA, Adetifa IM, de Jong BC, Aiken AM, et al: Longitudinal assessment of an ELISPOT test for Mycobacterium tuberculosis infection. PLoS Med. 2007, 4: e192-10.1371/journal.pmed.0040192.CrossRefPubMedPubMedCentral
11.
Hill PC, Jeffries DJ, Brookes RH, Fox A, Jackson-Sillah D, Lugos MD, Donkor SA, de Jong BC, Corrah T, Adegbola RA, McAdam KP: Using ELISPOT to expose false positive skin test conversion in tuberculosis contacts. PLoS ONE. 2007, 2: e183-10.1371/journal.pone.0000183.CrossRefPubMedPubMedCentral
12.
Pai M, Joshi R, Dogra S, Zwerling AA, Gajalakshmi D, Goswami K, Reddy MV, Kalantri A, Hill PC, Menzies D, Hopewell PC: T-cell assay conversions and reversions among household contacts of tuberculosis patients in rural India. Int J Tuberc Lung Dis. 2009, 13: 84-92.PubMedPubMedCentral
13.
Ewer K, Millington KA, Deeks JJ, Alvarez L, Bryant G, Lalvani A: Dynamic antigen-specific T-cell responses after point-source exposure to Mycobacterium tuberculosis. Am J Respir Crit Care Med. 2006, 174: 831-839. 10.1164/rccm.200511-1783OC.CrossRefPubMed
14.
Pai M, Joshi R, Dogra S, Mendiratta DK, Narang P, Dheda K, Kalantri S: Persistently elevated T cell interferon-gamma responses after treatment for latent tuberculosis infection among health care workers in India: a preliminary report. J Occup Med Toxicol. 2006, 1: 7-10.1186/1745-6673-1-7.CrossRefPubMedPubMedCentral
15.
Katiyar SK, Sampath A, Bihari S, Mamtani M, Kulkarni H: Use of the QuantiFERON-TB Gold In-Tube test to monitor treatment efficacy in active pulmonary tuberculosis. Int J Tuberc Lung Dis. 2008, 12: 1146-1152.PubMed
16.
Pollock NR, Kashino SS, Napolitano DR, Sloutsky A, Joshi S, Guillet J, Wong M, Nardell E, Campos-Neto A: Evaluation of the effect of treatment of latent tuberculosis infection on QuantiFERON-TB gold assay results. Infect Control Hosp Epidemiol. 2009, 30: 392-395. 10.1086/596606.CrossRefPubMedPubMedCentral
17.
Ribeiro S, Dooley K, Hackman J, Loredo C, Efron A, Chaisson RE, Conde MB, Boechat N, Dorman SE: T-SPOT.TB responses during treatment of pulmonary tuberculosis. BMC Infect Dis. 2009, 9: 23-10.1186/1471-2334-9-23.CrossRefPubMedPubMedCentral
18.
Veerapathran A, Joshi R, Goswami K, Dogra S, Moodie EE, Reddy MV, Kalantri S, Schwartzman K, Behr MA, Menzies D, Pai M: T-cell assays for tuberculosis infection: deriving cut-offs for conversions using reproducibility data. PLoS ONE. 2008, 3: e1850-10.1371/journal.pone.0001850.CrossRefPubMedPubMedCentral
19.
Detjen AK, Loebenberg L, Grewal HM, Stanley K, Gutschmidt A, Kruger C, Du Plessis N, Kidd M, Beyers N, Walzl G, Hesseling AC: Short-term reproducibility of a commercial interferon gamma release assay. Clin Vaccine Immunol. 2009, 16: 1170-1175. 10.1128/CVI.00168-09.CrossRefPubMedPubMedCentral
20.
van Zyl-Smit RN, Pai M, Peprah K, Meldau R, Kieck J, Juritz J, Badri M, Zumla A, Sechi LA, Bateman ED, Dheda K: Within-subject variability and boosting of T-cell interferon-gamma responses after tuberculin skin testing. Am J Respir Crit Care Med. 2009, 180: 49-58. 10.1164/rccm.200811-1704OC.CrossRefPubMed
21.
Chee CB, Lim LK, Barkham TM, Koh DR, Lam SO, Shen L, Wang YT: Use of a T cell interferon-gamma release assay to evaluate tuberculosis risk in newly qualified physicians in Singapore healthcare institutions. Infect Control Hosp Epidemiol. 2009, 30: 870-875. 10.1086/599284.CrossRefPubMed
22.
Yoshiyama T, Harada N, Higuchi K, Nakajima Y, Ogata H: Estimation of incidence of tuberculosis infection in health-care workers using repeated interferon-gamma assays. Epidemiol Infect. 2009, 1-8.
23.
Franken WP, Koster BF, Bossink AW, Thijsen SF, Bouwman JJ, van Dissel JT, Arend SM: Follow-up study of tuberculosis-exposed supermarket customers with negative tuberculin skin test results in association with positive gamma interferon release assay results. Clin Vaccine Immunol. 2007, 14: 1239-1241. 10.1128/CVI.00185-07.CrossRefPubMedPubMedCentral
24.
Franken WP, Arend SM, Thijsen SF, Bouwman JJ, Koster BF, van Dissel JT, Bossink AW: Interferon-gamma release assays during follow-up of tuberculin skin test-positive contacts. Int J Tuberc Lung Dis. 2008, 12: 1286-1294.PubMed
25.
Perry S, Sanchez L, Yang S, Agarwal Z, Hurst P, Parsonnet J: Reproducibility of QuantiFERON-TB gold in-tube assay. Clin Vaccine Immunol. 2008, 15: 425-432. 10.1128/CVI.00398-07.CrossRefPubMedPubMedCentral
26.
Brodhun B, Altmann D, Haas W: [Report on the epidemiology of tuberculosis in Germany 2007]. 2009, Berlin: Robert Koch-Institut (RKI)
27.
Centers for Disease Control and Prevention: Guidelines for preventing the transmission of Mycobacterium tuberculosis in health-care settings, 2005. MMWR Recomm Rep. 2005, 54 (RR-17): 1-141.
28.
Ringshausen FC, Schlosser S, Nienhaus A, Schablon A, Schultze-Werninghaus G, Rohde G: In-hospital contact investigation among health care workers after exposure to smear-negative tuberculosis. J Occup Med Toxicol. 2009, 4: 11-10.1186/1745-6673-4-11.CrossRefPubMedPubMedCentral
29.
30.
Hosmer D, Lemeshow S: Applied logistic regression. 2000, New York, NY: John Wiley & Sons, 2CrossRef
31.
Nienhaus A, Schablon A, Bacle CL, Siano B, Diel R: Evaluation of the interferon-gamma release assay in healthcare workers. Int Arch Occup Environ Health. 2008, 81: 295-300. 10.1007/s00420-007-0212-1.CrossRefPubMed
32.
Nienhaus A, Schablon A, Diel R: Interferon-gamma release assay for the diagnosis of latent TB infection--analysis of discordant results, when compared to the tuberculin skin test. PLoS ONE. 2008, 3: e2665-10.1371/journal.pone.0002665.CrossRefPubMedPubMedCentral
33.
Vinton P, Mihrshahi S, Johnson P, Jenkin GA, Jolley D, Biggs BA: Comparison of QuantiFERON-TB Gold In-Tube Test and tuberculin skin test for identification of latent Mycobacterium tuberculosis infection in healthcare staff and association between positive test results and known risk factors for infection. Infect Control Hosp Epidemiol. 2009, 30: 215-221. 10.1086/595695.CrossRefPubMed
34.
Richeldi L, Ewer K, Losi M, Roversi P, Fabbri LM, Lalvani A: Repeated tuberculin testing does not induce false positive ELISPOT results. Thorax. 2006, 61: 180-10.1136/thx.2005.049759.CrossRefPubMedPubMedCentral
35.
van Zyl-Smit RN, Zwerling A, Dheda K, Pai M: Within-subject variability of interferon-g assay results for tuberculosis and boosting effect of tuberculin skin testing: a systematic review. PLoS One. 2009, 4: e8517-10.1371/journal.pone.0008517.CrossRefPubMedPubMedCentral
36.
Harada N, Nakajima Y, Higuchi K, Sekiya Y, Rothel J, Mori T: Screening for tuberculosis infection using whole-blood interferon-gamma and Mantoux testing among Japanese healthcare workers. Infect Control Hosp Epidemiol. 2006, 27: 442-448. 10.1086/504358.CrossRefPubMed
37.
Bakir M, Millington KA, Soysal A, Deeks JJ, Efee S, Aslan Y, Dosanjh DP, Lalvani A: Prognostic value of a T-cell-based, interferon-gamma biomarker in children with tuberculosis contact. Ann Intern Med. 2008, 149: 777-787.CrossRefPubMedPubMedCentral
38.
Diel R, Loddenkemper R, Meywald-Walter K, Niemann S, Nienhaus A: Predictive value of a whole blood IFN-gamma assay for the development of active tuberculosis disease after recent infection with Mycobacterium tuberculosis. Am J Respir Crit Care Med. 2008, 177: 1164-1170. 10.1164/rccm.200711-1613OC.CrossRefPubMed
39.
Hill PC, Jackson-Sillah DJ, Fox A, Brookes RH, de Jong BC, Lugos MD, Adetifa IM, Donkor SA, Aiken AM, Howie SR, et al: Incidence of tuberculosis and the predictive value of ELISPOT and Mantoux tests in Gambian case contacts. PLoS ONE. 2008, 3: e1379-10.1371/journal.pone.0001379.CrossRefPubMedPubMedCentral
40.
Haldar P, Thuraisingham H, Hoskyns W, Woltmann G: Contact screening with single-step TIGRA testing and risk of active TB infection: the Leicester cohort analysis [abstract]. Thorax. 2009, 64 (Suppl IV): A10-
41.
Kik SV, Franken WP, Mensen M, Cobelens FG, Kamphorst M, Arend SM, Erkens C, Gebhard A, Borgdorff MW, Verver S: Predictive value for progression to tuberculosis by IGRA and TST in immigrant contacts. Eur Respir J. 2010, 35: 1346-53. 10.1183/09031936.00098509.CrossRefPubMed
42.
Andersen P, Doherty TM, Pai M, Weldingh K: The prognosis of latent tuberculosis: can disease be predicted?. Trends Mol Med. 2007, 13: 175-182. 10.1016/j.molmed.2007.03.004.CrossRefPubMed
43.
Pai M: Spectrum of latent tuberculosis - existing tests cannot resolve the underlying phenotypes. Nat Rev Microbiol. 2010, 8: 242-10.1038/nrmicro2236-c1.CrossRefPubMed
44.
Pai M, O'Brien R: Serial testing for tuberculosis: can we make sense of T cell assay conversions and reversions?. PLoS Med. 2007, 4: e208-10.1371/journal.pmed.0040208.CrossRefPubMedPubMedCentral
45.
Pai M, Zwerling A, Menzies D: Systematic review: T-cell-based assays for the diagnosis of latent tuberculosis infection: an update. Ann Intern Med. 2008, 149: 177-184.CrossRefPubMedPubMedCentral
46.
Ringshausen FC, Tannapfel A, Nicolas V, Weber A, Duchna HW, Schultze-Werninghaus G, Rohde G: A fatal case of spinal tuberculosis mistaken for metastatic lung cancer: recalling ancient Pott's disease. Ann Clin Microbiol Antimicrob. 2009, 8: 32-10.1186/1476-0711-8-32.CrossRefPubMedPubMedCentral
47.
Ringshausen FC, Schlösser S, Schablon A, Nienhaus A, Schultze-Werninghaus G, Rohde G: Frequency of discordant results in interferon-gamma release assay serial testing for latent tuberculosis infection in health care workers [abstract]. Eur Respir J. 2008, 32 (Suppl 52): 447s-
48.
Ringshausen FC, Nienhaus A, Schablon A, Schlösser S, Schultze-Werninghaus G, Rohde G: Predictors of consistently positive Mycobacterium-tuberculosis-specific interferon-gamma responses in the serial testing of health care workers [abstract]. Swiss Medical Forum. 2010, 10 (Suppl 50): 9s-
Metadata
Title
Predictors of persistently positive Mycobacterium-tuberculosis-specific interferon-gamma responses in the serial testing of health care workers
Publication date
01-12-2010
Published in
BMC Infectious Diseases / Issue 1/2010
Electronic ISSN: 1471-2334
DOI
https://doi.org/10.1186/1471-2334-10-220

Other articles of this Issue 1/2010

BMC Infectious Diseases 1/2010 Go to the issue

Research article

Genetic diversity of Mycobacterium tuberculosis Complex in Jos, Nigeria

Research article

Avoidance behaviors and negative psychological responses in the general population in the initial stage of the H1N1 pandemic in Hong Kong

Research article

Large screening of CA-MRSA among Staphylococcus aureus colonizing healthy young children living in two areas (urban and rural) of Portugal

Research article

High rate of pneumococcal bacteremia in a prospective cohort of older children and adults in an area of high HIV prevalence in rural western Kenya

Research article

Changes of tau profiles in brains of the hamsters infected with scrapie strains 263 K or 139 A possibly associated with the alteration of phosphate kinases

Research article

Epidemiology of nasopharyngeal carriage of respiratory bacterial pathogens in children and adults: cross-sectional surveys in a population with high rates of pneumococcal disease
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits